Annual FCF
-$55.57 M
-$20.88 M-60.17%
31 December 2023
Summary:
Armata Pharmaceuticals annual free cash flow is currently -$55.57 million, with the most recent change of -$20.88 million (-60.17%) on 31 December 2023. During the last 3 years, it has fallen by -$36.47 million (-191.02%). ARMP annual FCF is now -1532.88% below its all-time high of -$3.40 million, reached on 31 December 2000.ARMP Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$9.20 M
+$2.34 M+20.27%
30 September 2024
Summary:
Armata Pharmaceuticals quarterly free cash flow is currently -$9.20 million, with the most recent change of +$2.34 million (+20.27%) on 30 September 2024. Over the past year, it has increased by +$4.00 million (+30.28%). ARMP quarterly FCF is now -291.93% below its all-time high of $4.80 million, reached on 30 September 2000.ARMP Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$42.09 M
+$4.00 M+8.67%
30 September 2024
Summary:
Armata Pharmaceuticals TTM free cash flow is currently -$42.09 million, with the most recent change of +$4.00 million (+8.67%) on 30 September 2024. Over the past year, it has increased by +$13.01 million (+23.61%). ARMP TTM FCF is now -3661.04% below its all-time high of -$1.12 million, reached on 31 March 2013.ARMP TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARMP Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -60.2% | +30.3% | +23.6% |
| 3 y3 years | -191.0% | -65.9% | -85.2% |
| 5 y5 years | -489.5% | -104.4% | -188.9% |
ARMP Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -191.0% | at low | -145.3% | +53.0% | -85.2% | +24.3% |
| 5 y | 5 years | -489.5% | at low | -234.7% | +53.0% | -188.9% | +24.3% |
| alltime | all time | -1532.9% | at low | -291.9% | +53.0% | -3661.0% | +24.3% |
Armata Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.20 M(-20.3%) | -$42.09 M(-8.7%) |
| June 2024 | - | -$11.54 M(+6.5%) | -$46.08 M(-1.6%) |
| Mar 2024 | - | -$10.83 M(+3.1%) | -$46.82 M(-15.7%) |
| Dec 2023 | -$55.57 M(+60.2%) | -$10.51 M(-20.4%) | -$55.57 M(+0.9%) |
| Sept 2023 | - | -$13.20 M(+7.5%) | -$55.09 M(+2.9%) |
| June 2023 | - | -$12.28 M(-37.3%) | -$53.52 M(+5.9%) |
| Mar 2023 | - | -$19.58 M(+95.2%) | -$50.52 M(+45.6%) |
| Dec 2022 | -$34.69 M(+39.4%) | -$10.03 M(-13.7%) | -$34.69 M(+3.6%) |
| Sept 2022 | - | -$11.63 M(+25.2%) | -$33.49 M(+22.2%) |
| June 2022 | - | -$9.28 M(+147.5%) | -$27.41 M(+19.9%) |
| Mar 2022 | - | -$3.75 M(-57.5%) | -$22.86 M(-8.1%) |
| Dec 2021 | -$24.88 M(+30.3%) | -$8.83 M(+59.1%) | -$24.88 M(+9.5%) |
| Sept 2021 | - | -$5.55 M(+17.2%) | -$22.72 M(+7.5%) |
| June 2021 | - | -$4.73 M(-18.0%) | -$21.14 M(+2.9%) |
| Mar 2021 | - | -$5.77 M(-13.4%) | -$20.53 M(+7.5%) |
| Dec 2020 | -$19.09 M(+20.8%) | -$6.67 M(+68.3%) | -$19.09 M(+25.8%) |
| Sept 2020 | - | -$3.96 M(-4.1%) | -$15.18 M(-3.4%) |
| June 2020 | - | -$4.13 M(-4.8%) | -$15.72 M(-10.4%) |
| Mar 2020 | - | -$4.34 M(+57.7%) | -$17.54 M(+11.0%) |
| Dec 2019 | -$15.81 M(+67.7%) | -$2.75 M(-38.9%) | -$15.81 M(+8.5%) |
| Sept 2019 | - | -$4.50 M(-24.4%) | -$14.57 M(+19.0%) |
| June 2019 | - | -$5.95 M(+128.9%) | -$12.24 M(+44.2%) |
| Mar 2019 | - | -$2.60 M(+72.3%) | -$8.49 M(-9.9%) |
| Dec 2018 | -$9.43 M(+1.9%) | -$1.51 M(-30.6%) | -$9.43 M(-8.5%) |
| Sept 2018 | - | -$2.18 M(-1.3%) | -$10.30 M(+17.7%) |
| June 2018 | - | -$2.20 M(-37.7%) | -$8.75 M(-7.7%) |
| Mar 2018 | - | -$3.54 M(+48.1%) | -$9.48 M(+2.5%) |
| Dec 2017 | -$9.25 M(-15.0%) | -$2.39 M(+281.3%) | -$9.25 M(+10.5%) |
| Sept 2017 | - | -$626.00 K(-78.7%) | -$8.37 M(-23.2%) |
| June 2017 | - | -$2.93 M(-11.2%) | -$10.91 M(-0.8%) |
| Mar 2017 | - | -$3.30 M(+118.7%) | -$10.99 M(+1.0%) |
| Dec 2016 | -$10.88 M(+8.9%) | -$1.51 M(-52.2%) | -$10.88 M(-7.3%) |
| Sept 2016 | - | -$3.16 M(+4.7%) | -$11.74 M(+4.9%) |
| June 2016 | - | -$3.02 M(-5.6%) | -$11.19 M(+3.2%) |
| Mar 2016 | - | -$3.20 M(+35.1%) | -$10.85 M(+8.6%) |
| Dec 2015 | -$9.99 M(-27.5%) | -$2.37 M(-9.4%) | -$9.99 M(-7.7%) |
| Sept 2015 | - | -$2.61 M(-2.2%) | -$10.83 M(-1.4%) |
| June 2015 | - | -$2.67 M(+14.1%) | -$10.98 M(-10.0%) |
| Mar 2015 | - | -$2.34 M(-27.0%) | -$12.19 M(-11.5%) |
| Dec 2014 | -$13.77 M(+115.4%) | -$3.21 M(+16.0%) | -$13.77 M(+14.9%) |
| Sept 2014 | - | -$2.76 M(-28.9%) | -$11.99 M(+2.0%) |
| June 2014 | - | -$3.88 M(-0.9%) | -$11.75 M(+27.8%) |
| Mar 2014 | - | -$3.92 M(+176.6%) | -$9.20 M(+43.8%) |
| Dec 2013 | -$6.39 M(+47.5%) | -$1.42 M(-43.9%) | -$6.39 M(+28.5%) |
| Sept 2013 | - | -$2.53 M(+89.6%) | -$4.98 M(+103.1%) |
| June 2013 | - | -$1.33 M(+19.0%) | -$2.45 M(+119.0%) |
| Mar 2013 | - | -$1.12 M(-189.7%) | -$1.12 M(-79.5%) |
| Dec 2012 | -$4.33 M(-60.8%) | - | - |
| Sept 2009 | - | $1.25 M(-186.2%) | -$5.47 M(-45.6%) |
| June 2009 | - | -$1.45 M(+11.3%) | -$10.05 M(+14.7%) |
| Mar 2009 | - | -$1.30 M(-67.2%) | -$8.76 M(-20.6%) |
| Dec 2008 | -$11.04 M | -$3.97 M(+18.9%) | -$11.04 M(+0.4%) |
| Sept 2008 | - | -$3.34 M(+1972.0%) | -$11.00 M(-8.5%) |
| June 2008 | - | -$161.00 K(-95.5%) | -$12.02 M(-19.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$3.58 M(-8.8%) | -$14.98 M(+3.7%) |
| Dec 2007 | -$14.44 M(+23.2%) | -$3.92 M(-10.0%) | -$14.44 M(+14.2%) |
| Sept 2007 | - | -$4.36 M(+39.9%) | -$12.64 M(+13.1%) |
| June 2007 | - | -$3.12 M(+2.6%) | -$11.17 M(-5.7%) |
| Mar 2007 | - | -$3.04 M(+43.1%) | -$11.85 M(+1.1%) |
| Dec 2006 | -$11.72 M(-31.3%) | -$2.12 M(-26.7%) | -$11.72 M(-7.0%) |
| Sept 2006 | - | -$2.90 M(-23.5%) | -$12.60 M(-19.3%) |
| June 2006 | - | -$3.79 M(+30.3%) | -$15.61 M(-5.3%) |
| Mar 2006 | - | -$2.91 M(-3.3%) | -$16.49 M(-3.3%) |
| Dec 2005 | -$17.06 M(+7.1%) | -$3.01 M(-49.1%) | -$17.06 M(-1.5%) |
| Sept 2005 | - | -$5.91 M(+26.5%) | -$17.33 M(+1.5%) |
| June 2005 | - | -$4.67 M(+34.4%) | -$17.07 M(+7.3%) |
| Mar 2005 | - | -$3.47 M(+6.1%) | -$15.91 M(-0.1%) |
| Dec 2004 | -$15.93 M(+38.0%) | -$3.27 M(-42.1%) | -$15.93 M(-9.0%) |
| Sept 2004 | - | -$5.66 M(+61.3%) | -$17.51 M(+15.7%) |
| June 2004 | - | -$3.51 M(+0.4%) | -$15.13 M(+1.2%) |
| Mar 2004 | - | -$3.49 M(-28.0%) | -$14.95 M(+29.5%) |
| Dec 2003 | -$11.55 M(-44.1%) | -$4.85 M(+48.1%) | -$11.55 M(-5.4%) |
| Sept 2003 | - | -$3.28 M(-1.6%) | -$12.20 M(-4.8%) |
| June 2003 | - | -$3.33 M(+3641.6%) | -$12.82 M(-11.6%) |
| Mar 2003 | - | -$89.00 K(-98.4%) | -$14.50 M(-29.8%) |
| Dec 2002 | -$20.66 M(-26.1%) | -$5.51 M(+41.3%) | -$20.66 M(-10.5%) |
| Sept 2002 | - | -$3.90 M(-22.2%) | -$23.08 M(-6.7%) |
| June 2002 | - | -$5.01 M(-19.7%) | -$24.73 M(-10.4%) |
| Mar 2002 | - | -$6.24 M(-21.2%) | -$27.60 M(-1.3%) |
| Dec 2001 | -$27.95 M(+721.5%) | -$7.93 M(+42.7%) | -$27.95 M(+22.0%) |
| Sept 2001 | - | -$5.55 M(-29.5%) | -$22.91 M(+82.4%) |
| June 2001 | - | -$7.88 M(+19.4%) | -$12.56 M(+86.4%) |
| Mar 2001 | - | -$6.60 M(+128.7%) | -$6.74 M(+98.1%) |
| Dec 2000 | -$3.40 M(-72.8%) | -$2.89 M(-160.2%) | -$3.40 M(+16.6%) |
| Sept 2000 | - | $4.80 M(-333.7%) | -$2.92 M(-73.7%) |
| June 2000 | - | -$2.05 M(-37.1%) | -$11.11 M(-10.1%) |
| Mar 2000 | - | -$3.26 M(+35.9%) | -$12.36 M(-1.1%) |
| Dec 1999 | -$12.50 M(+108.3%) | -$2.40 M(-29.4%) | -$12.50 M(+86.6%) |
| Sept 1999 | - | -$3.40 M(+3.0%) | -$6.70 M(+3.1%) |
| June 1999 | - | -$3.30 M(-2.9%) | -$6.50 M(0.0%) |
| Mar 1999 | - | -$3.40 M(-200.0%) | -$6.50 M(+8.3%) |
| Dec 1998 | -$6.00 M(-54.5%) | $3.40 M(-206.3%) | -$6.00 M(-54.5%) |
| Sept 1998 | - | -$3.20 M(-3.0%) | -$13.20 M(+7.3%) |
| June 1998 | - | -$3.30 M(+13.8%) | -$12.30 M(-1.6%) |
| Mar 1998 | - | -$2.90 M(-23.7%) | -$12.50 M(-5.3%) |
| Dec 1997 | -$13.20 M(+10.9%) | -$3.80 M(+65.2%) | -$13.20 M(+7.3%) |
| Sept 1997 | - | -$2.30 M(-34.3%) | -$12.30 M(-0.8%) |
| June 1997 | - | -$3.50 M(-2.8%) | -$12.40 M(0.0%) |
| Mar 1997 | - | -$3.60 M(+24.1%) | -$12.40 M(+4.2%) |
| Dec 1996 | -$11.90 M(+21.4%) | -$2.90 M(+20.8%) | -$11.90 M(+8.2%) |
| Sept 1996 | - | -$2.40 M(-31.4%) | -$11.00 M(-1.8%) |
| June 1996 | - | -$3.50 M(+12.9%) | -$11.20 M(+9.8%) |
| Mar 1996 | - | -$3.10 M(+55.0%) | -$10.20 M(+4.1%) |
| Dec 1995 | -$9.80 M(+21.0%) | -$2.00 M(-23.1%) | -$9.80 M(+25.6%) |
| Sept 1995 | - | -$2.60 M(+4.0%) | -$7.80 M(+50.0%) |
| June 1995 | - | -$2.50 M(-7.4%) | -$5.20 M(+92.6%) |
| Mar 1995 | - | -$2.70 M | -$2.70 M |
| Dec 1994 | -$8.10 M(-9.0%) | - | - |
| Dec 1993 | -$8.90 M | - | - |
FAQ
- What is Armata Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals annual FCF year-on-year change?
- What is Armata Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals quarterly FCF year-on-year change?
- What is Armata Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals TTM FCF year-on-year change?
What is Armata Pharmaceuticals annual free cash flow?
The current annual FCF of ARMP is -$55.57 M
What is the all time high annual FCF for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high annual free cash flow is -$3.40 M
What is Armata Pharmaceuticals annual FCF year-on-year change?
Over the past year, ARMP annual free cash flow has changed by -$20.88 M (-60.17%)
What is Armata Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of ARMP is -$9.20 M
What is the all time high quarterly FCF for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high quarterly free cash flow is $4.80 M
What is Armata Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, ARMP quarterly free cash flow has changed by +$4.00 M (+30.28%)
What is Armata Pharmaceuticals TTM free cash flow?
The current TTM FCF of ARMP is -$42.09 M
What is the all time high TTM FCF for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high TTM free cash flow is -$1.12 M
What is Armata Pharmaceuticals TTM FCF year-on-year change?
Over the past year, ARMP TTM free cash flow has changed by +$13.01 M (+23.61%)